Global Congenital Diaphragmatic Hernia Drugs Market, By Type (Bochdalek Hernia, Morgagni Hernia Diaphragm), Treatment (Extracorporeal Membrane Oxygenation, Others), Diagnosis (Prenatal, Postnatal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Congenital Diaphragmatic Hernia Drugs Market Analysis and Size
The congenital diaphragmatic hernia drugs market is expected to witness significant growth during the forecast period. Newer treatment modalities, including antenatal screening and intervention, are available but are often presented without formal evaluation. The occurrence of CDH ranges from 1.6 - 5.7 per 10,000 live-born infants depending on the epidemiology. Significant infant mortality and morbidity can be witnessed as factors responsible for the growth of the congenital diaphragmatic hernia drugs market.
Data Bridge Market Research analyses a growth rate in the congenital diaphragmatic hernia drugs market in the forecast period 2023-2030. The expected CAGR of congenital diaphragmatic hernia drugs market is tend to be around 7% in the mentioned forecast period. The market was valued at USD 4 billion in 2022, and it would grow upto USD 6.87 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Congenital Diaphragmatic Hernia Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Bochdalek Hernia, Morgagni Hernia Diaphragm), Treatment (Extracorporeal Membrane Oxygenation, Others), Diagnosis (Prenatal, Postnatal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Johnson & Johnson Services, Inc. (U.S.), Integra LifeSciences (U.S.), B. Braun SE (Germany), C.R. Bard, Inc. (US), Cook (U.S.), W. L. Gore & Associates, Inc. (U.S.), Dipromed Srl (Italy)
|
|
Market Opportunities
|
|
Market Definition
Congenital diaphragmatic hernia (CDH) is an uncommon congenital malformation of the lung. It is related with high mortality and although improvements in medical and surgical management have improved the outlook, the survival remains at 60–70%. A baby suffering from CDH can suffer from a form of underdeveloped lungs known as pulmonary hypoplasia. Because fetal activity and breathing movements become more common and vigorous as the pregnancy continues, the amount of herniation can fluctuate or increase.
Global Congenital Diaphragmatic Hernia Drugs Market Dynamics
Drivers
- Availability of advanced treatment procedures
With each passing decade, diverse treatment methods are available that would help the patients' faster recovery. Congenital diaphragmatic hernia (CDH) is treated with drugs such as fetal surveillance and delivery planning, Fetoscopic tracheal occlusion (FETO). It would help better understand the disease and boost market growth. Thus, it acts as a major driver in the market growth.
- Increase in the number of research and development activities
The market's growth is fuelled by an rise in the number of R&D activities. This will provide beneficial opportunities for the global congenital diaphragmatic hernia (CDH) market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding R&D initiatives.
Opportunities
- Increased demands of diagnostic tests
Congenital diaphragmatic hernia (CDH) patients undergo several tests to determine that autoantibodies responsible for this syndrome are present in an affected individual. To confirm a prenatal diagnosis of CDH, consultants may perform a very detailed ultrasound, conduct testing of the fetus’s chromosomes and take measurements of its lung size. During the ultrasound, specialists focus on precise findings that may point to a syndrome's presence. All these factors are also contributing in the growth of the market.
- Increasing demand for retail pharmacies
Increase in the number of drugs for congenital diaphragmatic hernia (CDH) being delivered through retail pharmacies and surge in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Lack of awareness
The lack of awareness about these disorders and the unavailability of numerous awareness programs hamper the market growth. The available drugs have not shown disease-modifying activity and are still mostly inadequate for managing major unmet needs.
- High cost
The huge expenditure associated with these agents hamper the market growth. The huge drug development and associated processes hamper the market's growth.
This congenital diaphragmatic hernia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the congenital diaphragmatic hernia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Congenital Diaphragmatic Hernia Drugs Market Scope
The congenital diaphragmatic hernia drugs market is segmented on the basis of type, treatment, diagnosis, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Bochdalek Hernia
- Morgagni Hernia Diaphragm
Treatment
- Extracorporeal Membrane Oxygenation
- Others
Diagnosis
- Prenatal
- Postnatal
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Congenital Diaphragmatic Hernia Drugs Market Regional Analysis/Insights
The congenital diaphragmatic hernia drugs market is analyzed and market size insights and trends are provided by type, treatment, diagnosis, distribution channel and end-user as referenced above.
The major countries covered in the congenital diaphragmatic hernia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for congenital diaphragmatic hernia drugs market throughout the forecasted period due to increasing incidence of inguinal hernia, high demand for meshes.
North America dominates the market to high incidence of inguinal and umbilical hernia in countries such as China and India, an increasing geriatric population, changing lifestyles, and rising penetration of the major market players in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Congenital Diaphragmatic Hernia Drugs Market Share Analysis
The congenital diaphragmatic hernia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to congenital diaphragmatic hernia drugs market.
Key players operating in the congenital diaphragmatic hernia drugs market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson & Johnson Services, Inc. (U.S.)
- Integra LifeSciences (U.S.)
- B. Braun SE (Germany)
- C.R. Bard, Inc. (US)
- Cook (U.S.)
- W. L. Gore & Associates, Inc. (U.S.)
- Dipromed Srl (Italy)
SKU-